Image For Activity Cover
Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) (OnDemand)
Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)

HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)
Original Seminar Date November 2, 2023
6:00 pm ET - 7:30 pm ET

Program Overview

Hypertrophic cardiomyopathy (HCM) is estimated to affect some 700,000 Americans. Treatment usually includes the use of non-vasodilating beta-blockers followed by non-dihydropyridine calcium channel blockers if these therapies are not effective. Since the release of the most recent guidelines, mavacamten has been approved, and clinical trial data on emerging therapies including aficamten, ranolazine, and evolving gene therapies have been published. In our commitment to providing education that enhances clinical skills and improves patient outcomes, HFSA has identified a need for education in the selection and utilization of current and emerging therapies for HCM.


The HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) is part of the educational seminar series, featuring a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.

Target Audience
This activity is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.
Learning Objectives
  1. Review the genetics, pathophysiology, and diagnosis of hypertrophic cardiomyopathy.
  2. Discuss the clinical trial data and optimal use of current and emerging treatment options for the management of patients with hypertrophic cardiomyopathy.
  3. Identify advanced treatment options for the management of challenging patients with hypertrophic cardiomyopathy.
Program Planners and Faculty
Program PLanners:
  • Carolyn Y. Ho, MD

  • Carolyn Y. Ho, MD
  • Sharelene Day, MD
  • Victoria Parikh, MD
  • Lynne Warner Stevenson, MD
  • Michael Ayers, MD
  • Welcome Remarks - Carolyn Y. Ho, MD
  • Remembering the Basics: Diagnosis, Pathophysiology, and Genetics (Including the Family) -- Sharlene Day, MD
  • Management: The Usual Approach, Carolyn Y. Ho, MD
  • New Kids on the Block: New Medications and Future Approaches -- Victoria Parikh, MD
  • Q&A -- All Faculty
  • What Happens When the Usual is Not Enough: Referral and Advanced Therapy, Lynne Warner Stevenson, MD
  • Case Presentation: Mild LV Systolic Dysfunction, Michael Ayers, MD
  • What Happens When the Usual is Not Enough -- Lynne Warner Stevenson, MD, FHFSA
  • Moderated Discusson -- All faculty
  • Closing Remarks
Faculty Disclosures/Off-Label Disclosure

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:
  • Carolyn Y. Ho, MD: (Biomedical startup) - Advisory Panel
  • Sharlene Day, MD: Bristol-Myers Squibb (Pharmaceutical co.) - Research Support; Tenaya Therapeutics (Pharmaceutical co.) - Advisory Panel; Pfizer (Pharmaceutical co.) - Consultant; Cytokinetics (Pharmaceutical co.) - Data Monitoring Board; Biomarin (Pharmaceutical co.) - Consultant; Lexicon Pharmaceutical (pharmaceutical co.) - Consultant; Lexicon Pharmaceuticals (pharmaceutical co.) - Research Support.
  • Victoria Parikh, MD: No Disclosures
  • Lynne Warner Stevenson: No Disclosures
  • Michael Ayers, MD:  Bristol-Myers Squibb - Advisory Panel

Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Accreditation Statement

In support of improving patient care, the Heart Failure Society of American is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, includes participation in the post-course evaluation.

The Heart Failure Society of America acknowledge Bristol Myers Squibb and Cytokinetics for providing an independent educational grant to support the Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM).
  • Hypertrophic cardiomyopathy
  • HCM
  • non-vasodilating beta-blockers
  • non-dihydropyridine calcium channel blockers
  • mavacamten
  • aficamten
  • ranolazine
Availability: On-Demand
Expires on Nov 06, 2024
Cost: Member: $0.00
Non-Member: $59.00
Credit Offered:
1.5 CME Credits
Powered by Oasis.